[HTML][HTML] Unmet needs and challenges in gastric cancer: the way forward
F Lordick, W Allum, F Carneiro, E Mitry… - Cancer treatment …, 2014 - Elsevier
Although the incidence of gastric cancer has fallen steadily in developed countries over the
past 50 years, outcomes in Western countries remain poor, primarily due to the advanced …
past 50 years, outcomes in Western countries remain poor, primarily due to the advanced …
Tumor regression grading of gastrointestinal cancers after neoadjuvant therapy
R Langer, K Becker - Virchows Archiv, 2018 - Springer
Neoadjuvant therapy has been successfully introduced in the treatment of locally advanced
gastrointestinal malignancies, particularly esophageal, gastric, and rectal cancers. The …
gastrointestinal malignancies, particularly esophageal, gastric, and rectal cancers. The …
Neoadjuvant nivolumab plus ipilimumab and adjuvant nivolumab in localized deficient mismatch repair/microsatellite instability–high gastric or esophagogastric …
PURPOSE In patients with resectable gastric/gastroesophageal junction (GEJ)
adenocarcinoma, surgery plus perioperative platinum-based chemotherapy is the standard …
adenocarcinoma, surgery plus perioperative platinum-based chemotherapy is the standard …
Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in …
SE Al-Batran, RD Hofheinz, C Pauligk, HG Kopp… - The lancet …, 2016 - thelancet.com
Background Docetaxel-based chemotherapy is effective in metastatic gastric and gastro-
oesophageal junction adenocarcinoma, but has not yet been evaluated in the context of …
oesophageal junction adenocarcinoma, but has not yet been evaluated in the context of …
Human gastric cancer modelling using organoids
T Seidlitz, SR Merker, A Rothe, F Zakrzewski… - Gut, 2019 - gut.bmj.com
Objective Gastric cancer is the second leading cause of cancer-related deaths and the fifth
most common malignancy worldwide. In this study, human and mouse gastric cancer …
most common malignancy worldwide. In this study, human and mouse gastric cancer …
Development and validation of a computed tomography–based radiomics signature to predict response to neoadjuvant chemotherapy for locally advanced gastric …
W Wang, Y Peng, X Feng, Y Zhao… - JAMA network …, 2021 - jamanetwork.com
Importance Neoadjuvant therapies have been shown to decrease tumor burden, increase
resection rate, and improve the outcomes among patients with locally advanced gastric …
resection rate, and improve the outcomes among patients with locally advanced gastric …
Perioperative toripalimab and chemotherapy in locally advanced gastric or gastro-esophageal junction cancer: a randomized phase 2 trial
SQ Yuan, RC Nie, Y Jin, CC Liang, YF Li, R Jian… - Nature Medicine, 2024 - nature.com
Perioperative chemotherapy is the standard treatment for locally advanced gastric or gastro-
esophageal junction cancer, and the addition of programmed cell death 1 (PD-1) inhibitor is …
esophageal junction cancer, and the addition of programmed cell death 1 (PD-1) inhibitor is …
The Italian Research Group for Gastric Cancer (GIRCG) guidelines for gastric cancer staging and treatment: 2015
G De Manzoni, D Marrelli, GL Baiocchi, P Morgagni… - Gastric Cancer, 2017 - Springer
The Italian Research Group for Gastric Cancer (GIRCG) guidelines for gastric cancer
staging and treatment: 2015 | SpringerLink Skip to main content Advertisement …
staging and treatment: 2015 | SpringerLink Skip to main content Advertisement …
EORTC-1203-GITCG-the “INNOVATION”-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus …
AD Wagner, HI Grabsch, M Mauer, S Marreaud… - BMC cancer, 2019 - Springer
Abstract Background 10–20% of patients with gastric cancer (GC) have HER2+ tumors.
Addition of trastuzumab (T) to cisplatin/fluoropyrimidine-based chemotherapy (CT) improved …
Addition of trastuzumab (T) to cisplatin/fluoropyrimidine-based chemotherapy (CT) improved …
A phase II study of preoperative chemotherapy with docetaxel, cisplatin, and S-1 followed by gastrectomy with D2 plus para-aortic lymph node dissection for gastric …
S Ito, T Sano, J Mizusawa, D Takahari, H Katayama… - Gastric Cancer, 2017 - Springer
Background Gastric cancer with extensive lymph node metastasis is commonly considered
unresectable, with a poor prognosis. We previously reported the results of the use of …
unresectable, with a poor prognosis. We previously reported the results of the use of …